Abstract:Objective: The objective of this study was to investigate how L1 cell adhesion molecule (L1CAM) interacting with protein tyrosine kinase 2 (PTK2) affects endometrial cancer (EC) progression and determine its association with the focal adhesion kinase (FAK)–growth factor receptor-bound protein 2 (GRB2)–son of sevenless (SOS)–rat sarcoma (RAS) pathway. EC is a female cancer of major concern in the world, and its incidence has increased rapidly in recent years. L1CAM is considered a reliable marker of poor prognosis in patients with EC. Material and Methods: A single-center and prospective study was conducted using data from the Cancer Genome Atlas and samples from normal and EC tissues to explore the differential expression of L1CAM. Additional experimental models included human immortalized endometrial epithelium cells (hEECs) and EC cell lines such as KLE, RL95-2, and Ishikawa. L1CAM expression was regulated using lentiviruses designed for either overexpression or interference, and PTK2/focal adhesion kinase (FAK) signaling was inhibited with PF431396. Transfected KLE cells were injected into mice, and tumor growth was monitored over 14 days. Cellular proliferation and survival were assessed using cell counting kit, colony formation, and terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate (dUTP) nick-end labeling assays. Metastatic behavior was evaluated through Transwell assays for cell migration and invasion. The expression levels of matrix metallopeptidase (MMP) 2 and MMP9 were determined by Western blot. In addition, the activation of the FAK–GRB2–SOS–RAS pathway was examined by assessing the protein levels of FAK, GRB2, SOS, and RAS. Results: There was a significant difference in L1CAM expression between EC tumor tissues and normal tissues, and L1CAM messenger RNA (1.85-fold) and L1CAM protein (2.59-fold) were significantly more expressed in EC tissues (P < 0.01) than in normal tissues. The tumor growth of L1CAM overexpressing EC cells was faster than that of negative control EC cells (6.43 fold; P < 0.001). L1CAM promoted the expression of FAK (1.43-2.72-fold; P < 0.001); enhanced EC cell proliferation (P < 0.01), survival and motility (P < 0.001), migration (P < 0.001), and invasion (P < 0.001); and activated the FAK–GRB2–SOS–RAS pathway, all of which were reversed when FAK expression was not upregulated (P < 0.001). Conclusion: By upregulating PTK2 and its encoded protein FAK, L1CAM was found to promote tumor progression and increase the activation of the FAK–GRB2–SOS–RAS pathway. These findings establish L1CAM and PTK2 as reference genes for poor prognostic prediction in EC and as targets for EC therapy, providing a valuable basis for distinguishing between benign and malignant endometrial conditions and justifying the necessity of targeted therapeutic approaches.

Potential diagnostic biomarkers for human mesenchymal tumors, especially LMP2/b1i and cyclin E1 differential expression

Expression and Clinical Significance of Small Ubiquitin-Like Modifier-1 and P53 Protein in Uterine Leiomyosarcoma

STMN1 and MKI67 Are Upregulated in Uterine Leiomyosarcoma and Are Potential Biomarkers for Its Diagnosis

Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma

Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers

Secretome Profiling and Computational Biology of Human Leiomyoma Samples Unravel Molecular Signatures with Potential for Diagnostic and Therapeutic Interventions

[Expression and Significance of LMP2 and PPM1A in Gestational Trophoblastic Disease].

Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma

Abstract 6095: SMOC2 as a potential biomarker with diagnostic value in uterine leiomyosarcoma

The Immunohistochemical Expression of MCM-3, -5, and -7 Proteins in the Uterine Fibroids

Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma

Can EBP50 and Merlin be used as diagnostic and prognostic markers for uterine smooth muscle tumors?

Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review

Development of Uterine Leiomyosarcoma During Follow-up After Caesarean Section in a Woman With Uterine Leiomyoma

Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model

Diagnostic Value Of Progesterone Receptor, P16, P53 And Phh3 Expression In Uterine Atypical Leiomyoma

Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma

L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer

Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers

The mechanism of L1 cell adhesion molecule interacting with protein tyrosine kinase 2 to regulate the focal adhesion kinase–growth factor receptor-bound protein 2–son of sevenless–rat sarcoma pathway in the identification and treatment of type I high-risk endometrial cancer

Multivariate Analysis of Prognostic Biomarkers in Surgically Treated Endometrial Cancer